NeOnc to hold FDA meeting on NEO212 for glioma program
NeOnc Technologies said it will meet with the FDA on November 17, 2026 to discuss Phase 2 design for its brain cancer drug NEO212.
SEC filing
Latest
7 stories
Monday, September 28
Thursday, September 17
NeOnc CEO buys more stock after positive NEO100 Phase 2a data
Amir Heshmatpour purchased 35,000 additional NeOnc shares on September 15, 2026, bringing his and CMO Thomas Chen's combined open-market purchases to about $629,000 since August's trial results.
SEC filing
Thursday, September 10
NeOnc prices $15 million registered direct offering of stock and warrants
NeOnc Technologies Holdings priced a registered direct offering on September 8, 2026, with plans to use proceeds to redeem preferred stock and fund working capital.
SEC filing (2)
Friday, August 21
NeOnc Technologies amends filing to add Shomali's audit committee role
The company disclosed that Nasim Shomali joined the Audit Committee effective August 18, 2026, completing details left open in a July board appointment filing.
SEC filing
Thursday, August 13
NeOnc reports Phase 2a NEO100-01 met primary endpoint in recurrent IDH1 mutant glioma
In an August 12, 2026 investor call, NeOnc said NEO100 hit its PFS6 benchmark and reported a 26.1-month median overall survival in recurrent high-grade glioma patients.
SEC filing
Wednesday, August 12
NeOnc reports positive Phase 2a data for NEO100 in recurrent IDH1-mutant glioma
NeOnc Technologies plans to seek an FDA Type B meeting after intranasal NEO100 met its primary endpoint in a 24-patient study of recurrent high-grade glioma.
SEC filing
Monday, August 10
NeOnc confirms August 12 topline readout for Phase 2a NEO100 glioma study
The company reported second-quarter 2026 results, an FDA feedback session on NEO212, and cash of $2.0 million alongside undrawn credit facilities.
SEC filing